Optimal skeletal health is established during defined growth stages, with critical implications for the prevention of osteoporosis and fracture risk later in life. This review synthesizes current evidence and expert consensus on targeted strategies for preserving skeletal integrity across childhood, adolescence, and early adulthood. Emphasis is placed on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, evidence-based management, and recent advances in the field. The review aims to inform healthcare professionals about the mechanisms underlying skeletal accrual and the practical application of guideline-based interventions tailored to growth stages, thereby supporting lifelong bone health.
Bone development is a dynamic process that spans from fetal life, through childhood and adolescence, to early adulthood. The accrual of peak bone mass is a major determinant of future skeletal health, with up to 90% attained by the end of the second decade. Adverse influences during these critical growth stages, including nutritional deficiencies, hormonal imbalances, chronic disease, and sedentary lifestyle, can compromise bone strength and structure. This review provides doctors and healthcare professionals with a comprehensive synthesis of mechanistic insights, clinical considerations, and guideline-based strategies for optimizing skeletal health during periods of growth.
The global burden of osteoporotic fractures is substantial, with an estimated 9 million fractures annually worldwide. Evidence indicates that suboptimal peak bone mass often established during childhood and adolescence contributes significantly to fracture risk in later life. Epidemiological studies have shown that up to 60% of the variability in adult bone mass is determined by genetic and environmental factors during the first two decades of life. Nutritional inadequacies, physical inactivity, and chronic illness remain prevalent risk factors, particularly in low- and middle-income countries where dietary calcium and vitamin D deficiency are common. Increased prevalence of childhood obesity, sedentary behaviors, and early-onset chronic diseases further accentuate risk.
Bone modeling and remodeling are orchestrated by a balance between osteoblastic bone formation and osteoclastic bone resorption. During growth, bone accrual is driven by an interplay of systemic hormones, such as growth hormone (GH), insulin-like growth factor 1 (IGF-1), sex steroids, and local growth factors. The pubertal growth spurt is characterized by rapid increases in bone mass and cortical thickness, predominantly regulated by estrogen and testosterone. Deficiencies in key nutrients calcium, vitamin D, phosphorus, protein and chronic inflammation disrupt osteoblast-osteoclast coupling, impairing bone accrual. Furthermore, mechanical loading through physical activity stimulates bone formation via mechanotransduction mechanisms, while inactivity leads to increased resorption and trabecular thinning.
Risk factors for impaired skeletal accrual include genetic predisposition (e.g., familial low bone mass), inadequate dietary intake of calcium and vitamin D, chronic illnesses (e.g., juvenile idiopathic arthritis, inflammatory bowel disease), delayed puberty or hypogonadism, glucocorticoid therapy, malabsorption syndromes, eating disorders, and low physical activity levels. Obesity and metabolic syndrome paradoxically contribute to both increased bone size and reduced bone quality. Socioeconomic status, ethnicity, and cultural dietary practices also modulate risk profiles across populations.
Clinical manifestations of impaired bone health during growth are often subtle. Patients may present with recurrent fractures, particularly of the long bones, delayed skeletal maturation, deformities such as scoliosis or genu valgum, or reduced height velocity. In severe cases, features of rickets or osteomalacia may develop. Chronic musculoskeletal pain, reduced mobility, and compromised physical performance are additional indicators that warrant further investigation.
Diagnosis relies on comprehensive clinical evaluation, including detailed growth history, dietary assessment, physical examination, and identification of underlying chronic illnesses. Dual-energy X-ray absorptiometry (DXA) is the gold standard for assessing bone mineral density (BMD) in children and adolescents, with Z-scores adjusted for age, sex, and body size. Laboratory investigations encompass serum calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D, parathyroid hormone, and markers of bone turnover. In selected cases, genetic testing and imaging studies such as bone age assessment or vertebral morphometry may be indicated.
Management strategies prioritize modifiable factors during growth. Nutritional optimization is foundational, emphasizing adequate intake of calcium (1,000–1,300 mg/day depending on age), vitamin D (600–1,000 IU/day), protein, and micronutrients. Weight-bearing and resistance exercise should be encouraged to stimulate bone formation, with school- and community-based interventions demonstrating efficacy. Identification and management of underlying chronic diseases, hormonal deficiencies, or malabsorption are crucial. Pharmacological interventions (e.g., bisphosphonates) are reserved for select cases of severe osteoporosis or secondary bone disease, with careful monitoring for side effects.
Recent research has elucidated the role of the Wnt/β-catenin signaling pathway in bone formation, with novel agents such as sclerostin inhibitors (e.g., romosozumab) showing promise in adult populations. Their role in pediatric bone disorders is under investigation. Advances in genetic and molecular profiling allow for personalized risk assessment and targeted interventions. Nutritional genomics holds potential for optimizing dietary recommendations based on individual genetic predispositions. Wearable technologies and digital health interventions are emerging as tools to monitor physical activity and adherence to therapeutic regimens in pediatric populations.
Leading societies, including the International Osteoporosis Foundation and the Endocrine Society, recommend routine assessment of dietary calcium and vitamin D intake, promotion of regular weight-bearing physical activity, and early identification of at-risk children through clinical and family history. Screening for secondary causes of bone fragility is advised in children with recurrent fractures or chronic illnesses. Pharmacologic therapy should be considered only after optimizing modifiable factors and in consultation with a pediatric endocrinologist or bone specialist. Multidisciplinary care models are advocated for children with complex or chronic conditions affecting skeletal health.
Preserving skeletal health during growth stages is a cornerstone of lifelong fracture prevention and osteoporosis mitigation. Early identification of risk factors, evidence-based nutritional and lifestyle interventions, and judicious use of pharmacological therapies where indicated can significantly enhance peak bone mass accrual and reduce future disease burden. Continued research and clinical innovation are essential to further refine growth-stage strategies and personalize care for at-risk pediatric populations. Collaborative efforts between clinicians, families, and public health systems are paramount in safeguarding skeletal health for future generations.
1.
For MDS-Related Anemia, Telomerase Inhibitor Approved.
2.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Treating Depression: Crucial for Recovery From Fibromyalgia
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Immune Regulation of Blood Cell Development
3.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
4.
Transformative Frameworks in Oncology for Better Care
5.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation